Travere Therapeutics
Presencia
Travere Therapeutics es una de las ...
Travere Therapeutics es una empresa que cotiza bajo el símbolo de cotización TVTX (US).
Ejecutivos
Ver el organigrama con sus 20 ejecutivos principales
Biografías más buscadas en Travere Therapeutics
- Eric Dube, Director, President and Chief Executive Officer
- Tim Coughlin, Director
- Gary Lyons, Independent Chairman of the Board
Crear su alerta
para seguir los movimientos de los ejecutivos en Travere Therapeutics.
Biotecnología
Travere Therapeutics tiene 2.284 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Karius acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 3 de mayo de 2024).
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Travere Therapeutics
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | Travere Therapeutics, Inc.
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International | Travere Therapeutics, Inc.
- Travere Therapeutics Named a Finalist for the Citeline Awards Excellence in Rare Disease Drug Development
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association | Travere Therapeutics, Inc.
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Travere Therapeutics, Inc.
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at Upcoming Investor Conferences | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results | Travere Therapeutics, Inc.
- Biotech Breakthrough Awards Travere Therapeutics Overall Biopharma Company of the Year
- View more press releases Close
Redes sociales sobre Travere Therapeutics
- Travere Therapeutics en Wikipedia, Google News y Yahoo Finance
- Travere Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Eric Dube 
Llame a Travere Therapeutics al +1 646...
